Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors - Full Text View

Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors

This study is not yet open for participant recruitment.
Verified by Hadassah Medical Organization, July 2008

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00722228

Purpose

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with colorectal, gastric, ovarian, breast or lung epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals . This protocol is expected to prolong survival of metastatic epithelial cancer patients.

Condition	Intervention	Phase
Colorectal Cancer Ovarian Cancer Gastric Cancer Breast Cancer Lung Cancer	Biological: Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated	Phase I Phase II

Genetics Home Reference related topics:

breast cancer

MedlinePlus related topics:

Breast Cancer Cancer Colorectal Cancer Lung Cancer Ovarian Cancer Stomach Cancer

U.S. FDA Resources

Study Type:	Interventional

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Metastatic epithelial cancer
Above 18 years of age
Failure of at least one chemotherapy protocol
Clinical performance status of ECOG 0,1
Absolute neutrophil count greater than 1000/mm3
Serum ALT/AST less than three times the upper limit of normal
Serum creatinine less than or equal to 1.6 mg/dl.
Must be able to understand and sign the Informed Consent document

Exclusion Criteria:

Below 18 years of age
Women who are pregnant
Life expectancy of less than three months

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00722228

Contacts


Contact: Arik , Tzukert, DMD	: 00 972 2 6776095	arik@hadassah.org.il

Contact: Hadas , Lemberg, PhD	00 972 2 6777572	: lhadas@hadassah.org.il

Locations


Israel
	Hadassah Medical Organization
	Jerusalem, Israel, 91120

Sponsors and Collaborators

Hadassah Medical Organization

More Information

Study ID Numbers:	0359-08-HMO-CTIL
First Received:	July 23, 2008
Last Updated:	July 24, 2008
ClinicalTrials.gov Identifier:	NCT00722228
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:

Thoracic Neoplasms

Gonadal Disorders

Gastrointestinal Diseases

Colonic Diseases

Urogenital Neoplasms

Ovarian Diseases

Rectal Diseases

Genital Diseases, Female

Stomach Diseases

Respiratory Tract Diseases

Lung Neoplasms

Stomach Neoplasms

Breast Diseases

Endocrine Gland Neoplasms

Ovarian cancer

Digestive System Neoplasms

Ovarian Neoplasms

Skin Diseases

Genital Neoplasms, Female

Breast Neoplasms

Endocrine System Diseases

Stomach cancer

Intestinal Diseases

Intestinal Neoplasms

Digestive System Diseases

Lung Diseases

Gastrointestinal Neoplasms

Endocrinopathy

Colorectal Neoplasms

Additional relevant MeSH terms:

Respiratory Tract Neoplasms

Neoplasms

Neoplasms by Site

Adnexal Diseases

ClinicalTrials.gov processed this record on October 24, 2008